Compare Biocon Ltd with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs GSK PHARMA - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON GSK PHARMA BIOCON /
GSK PHARMA
 
P/E (TTM) x 25.9 33.8 76.6% View Chart
P/BV x 2.9 13.5 21.7% View Chart
Dividend Yield % 0.3 1.2 28.6%  

Financials

 BIOCON    GSK PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-19
GSK PHARMA
Mar-19
BIOCON /
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs7073,595 19.7%   
Low Rs5541,253 44.2%   
Sales per share (Unadj.) Rs91.9184.7 49.8%  
Earnings per share (Unadj.) Rs16.726.3 63.6%  
Cash flow per share (Unadj.) Rs24.229.2 82.9%  
Dividends per share (Unadj.) Rs1.0020.00 5.0%  
Dividend yield (eoy) %0.20.8 19.2%  
Book value per share (Unadj.) Rs101.6126.3 80.5%  
Shares outstanding (eoy) m600.00169.40 354.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.913.1 52.3%   
Avg P/E ratio x37.792.2 40.9%  
P/CF ratio (eoy) x26.183.1 31.4%  
Price / Book Value ratio x6.219.2 32.3%  
Dividend payout %6.076.1 7.9%   
Avg Mkt Cap Rs m378,330410,626 92.1%   
No. of employees `0006.15.0 123.6%   
Total wages/salary Rs m11,6535,372 216.9%   
Avg. sales/employee Rs Th8,994.36,306.7 142.6%   
Avg. wages/employee Rs Th1,900.71,083.1 175.5%   
Avg. net profit/employee Rs Th1,635.3898.0 182.1%   
INCOME DATA
Net Sales Rs m55,14431,281 176.3%  
Other income Rs m1,4441,023 141.1%   
Total revenues Rs m56,58832,304 175.2%   
Gross profit Rs m15,8836,009 264.3%  
Depreciation Rs m4,478486 921.4%   
Interest Rs m7096 11,816.7%   
Profit before tax Rs m12,1406,540 185.6%   
Minority Interest Rs m90-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0287 0.0%   
Tax Rs m2,1232,373 89.5%   
Profit after tax Rs m10,0264,454 225.1%  
Gross profit margin %28.819.2 149.9%  
Effective tax rate %17.536.3 48.2%   
Net profit margin %18.214.2 127.7%  
BALANCE SHEET DATA
Current assets Rs m48,22820,061 240.4%   
Current liabilities Rs m30,37614,543 208.9%   
Net working cap to sales %32.417.6 183.5%  
Current ratio x1.61.4 115.1%  
Inventory Days Days6857 120.3%  
Debtors Days Days8614 608.1%  
Net fixed assets Rs m64,13014,343 447.1%   
Share capital Rs m3,0001,694 177.1%   
"Free" reserves Rs m57,98019,704 294.3%   
Net worth Rs m60,98021,398 285.0%   
Long term debt Rs m15,7662 788,300.0%   
Total assets Rs m121,92439,113 311.7%  
Interest coverage x18.11,091.0 1.7%   
Debt to equity ratio x0.30 276,619.7%  
Sales to assets ratio x0.50.8 56.6%   
Return on assets %8.811.4 77.2%  
Return on equity %16.420.8 79.0%  
Return on capital %16.831.9 52.5%  
Exports to sales %28.10-   
Imports to sales %18.90-   
Exports (fob) Rs m15,506NA-   
Imports (cif) Rs m10,399NA-   
Fx inflow Rs m15,506534 2,903.7%   
Fx outflow Rs m10,3997,091 146.7%   
Net fx Rs m5,107-6,557 -77.9%   
CASH FLOW
From Operations Rs m11,5463,994 289.1%  
From Investments Rs m-7,138-1,433 498.0%  
From Financial Activity Rs m-2,417-3,584 67.4%  
Net Cashflow Rs m2,103-1,023 -205.5%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 50.7 40.6%  
Indian inst/Mut Fund % 8.4 10.2 82.4%  
FIIs % 10.7 23.8 45.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 15.4 129.2%  
Shareholders   109,995 102,036 107.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   DIVIS LABORATORIES  WOCKHARDT  VENUS REMEDIES  PANACEA BIOTECH  GLENMARK PHARMA  

Compare BIOCON With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade Lower; Tata Steel & HDFC Bank Top Losers(12:30 pm)

Share markets in India are presently trading lower amid weakness in global equities as investors grew anxious about the economic impact of China's spreading virus outbreak.

Related Views on News

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

Bet on These Smallcap Stocks for Success in 2020(Profit Hunter)

Jan 14, 2020

The smallcap rebound finally seems to here... Make sure you aren't too late to make the most of the biggest wealth making opportunity in a decade.

Guess Which Stocks Are Rising at Double the Speed of Sensex(Profit Hunter)

Jan 15, 2020

These stocks can move twice as fast as the Sensex - to take advantage of their money multiplying power get in now as the rally is still just taking shape.. read more to not miss out.

How to Buy the Best Safe Stocks in 2020(The 5 Minute Wrapup)

Jan 17, 2020

Don't fall for the safe stocks narrative going around in the stock market these days.

For 1,000%+ Gains, Follow the 8-Year Cycle in the Stock Market(Fast Profits Daily)

Jan 17, 2020

This is how the biggest trading profits are made.

What the Infosys Results Tell Us About the Next Infosys(The 5 Minute Wrapup)

Jan 15, 2020

If you're interested in the next Infosys, I'll tell you where to look.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Jan 27, 2020 12:37 PM

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS